We’re proud to announce that the Cystic Fibrosis Trust is funding three new Strategic Research Centres that will begin this autumn. This £2.2m investment over three years will involve 20 researchers from five different countries, who will tackle research priorities such as more effective treatments for lung infections and more effective, tailored treatments to improve lung clearance.
New training and equipment provided by the Trust’s Clinical Trials Accelerator Platform will ensure a wider range of clinical trials are accessible to the UK cystic fibrosis (CF) community.
The Cystic Fibrosis Trust has been awarded a grant for £2.5 million to investigate how artificial intelligence could revolutionise cystic fibrosis (CF) care. The research would allow thousands of people living with CF to monitor their health from home, reducing the burden of care and empowering them to have greater control over their condition.
This year marks the 10th anniversary of cystic fibrosis (CF) becoming part of the Guthrie heelprick test for newborn babies across the UK, as the last few health authorities across the country adopted the process. But the story of how we got there began in earnest way back with CF Week 1996 and the launch of the Cystic Fibrosis Trust’s newborn screening campaign, which would see the CF community raise its voice and change the way CF is understood and cared for, forever.
The Cystic Fibrosis Trust has announced further funding for the Gene Therapy Consortium (GTC), which could potentially support the first in-human clinical trials of their new gene therapy product. The investment complements additional investment the GTC has secured from the Wellcome Trust and Department of Health to continue their ground-breaking work.
Natalie has cystic fibrosis (CF) and has been training for the last year to run her first marathon for the Cystic Fibrosis Trust. In her third blog she tells us about the final chapter in her marathon journey, from pre-race nightmares to crossing the finish line.
